Sacituzumab govitecan vs platinum-based chemotherapy for Urothelial Carcinoma – ESMO
ESMO posted on X about recent paper by Petros Grivas et al., titled “LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): Overall survival (OS) and safety analysis” published on ESMO Annals of Oncology.
Authors: P. Grivas, T.B. Powles, C. Vulsteke, M. Gross Goupil, S.H. Park, A. Necchi, M. De Santis, I. Duran, R. Morales Barrera, J. Guo, C.N. Sternberg, J. Bellmunt, P.J. Goebell, F. Boateng, M. Sierecki, L. Wang, C. Sima, J. Waldes, S.T. Tagawa, Y. Loriot
“ESMO Asia24: The results of the phase III TROPiCS-04 study reveal that sacituzumab govitecan, while active in pre-treated patients with advanced Urothelial Carcinoma, did not significantly improve OS or PFS compared to platinum-based chemotherapy.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023